UnknownPhase 4

Randomized Anticoagulation Trial in Opcab (RATIO)

China, Italy900 participantsStarted 2017-01

Plain-language summary

The RATIO Study is a multicenter, nationwide, randomized, controlled, single blinded, unfunded trial of n. 900 patients undergoing multivessel OPCAB (≥2 grafts). This study is designed to test in patients undergoing off-pump coronary artery bypass surgery the hypothesis that full (high dose, 300 U/kg) and half (low dose,150 U/kg) heparinization are not different in terms of thrombotic complications and major perioperative bleeding events (null hypothesis).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Consecutive patients electively undergoing multivessel OPCAB Exclusion Criteria: Acute coronary syndrome, on-going double anti-platelets treatment (the second antiplatelet drug should be suspended 5 days before surgery), on-going intravenous heparin or sub-cutaneous low molecular weight heparin, known coagulopathy, documented liver disease, chronic renal failure (creatinine ≥ 2 mg/dl) or previous renal transplantation surgery, previous cardiac surgery.

What they're measuring

Composite vascular

Timeframe: 30 days post-operatively

Composite major bleeding

Timeframe: 48 hours post-operatively

Trial details

NCT IDNCT02812355

SponsorAzienda Ospedaliera di Lecco

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-01

Contact for this trial

Michele NR Triggiani, MD, PhD

+39-0341253066 m.triggiani@asst-lecco.it

View on ClinicalTrials.gov More Ischemic Heart Disease trials